36 results about "Precancerous condition" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to combined lactobacillus salivarius and application thereof in female genital tract health. The preservation number of the strain is CCTCC NO: M20231719, and the strain has good bacteriostatic ability and dendritic cell (DC) maturation / activation stimulation ability, has no potential safety problem, can regulate vaginal micro-ecological balance, prevent infection caused by exogenous bacteria, effectively improve tumor immunosuppression microenvironment, and has good application prospects. And the method has very important significance on prevention / treatment of vaginal dysbacteriosis patients, gynecological tumors and precancerous lesions thereof.

This invention discloses a wired dual-modal imaging capsule endoscopy system, belonging to the field of medical device technology. The system includes a capsule module, a transmission and control module, a dual-modal imaging module, and a signal analysis module. The capsule module is used to achieve 360° circumferential scanning imaging of the esophageal mucosa. The transmission and control module ensures stable transmission of optical and electrical signals and precise control of capsule movement. The dual-modal imaging module integrates an optical coherence tomography submodule and a photoacoustic imaging submodule to acquire tissue morphology information and microvascular distribution information, respectively. The signal analysis module processes the dual-modal signals. This invention achieves three-dimensional high-resolution integrated imaging of the esophageal mucosa without the need for exogenous labeling agents, significantly improving the detection accuracy of early esophageal cancer and precancerous lesions.

The present invention provides a computer implemented method for the prediction of clinical outcomes in patients with cancer or pre-neoplastic conditions through the integration of genomic evolutionary, genomic and clinical. More specifically, the invention provides systems and algorithms that generate prognostic and predictive models based on the combined analysis of molecular features, inferred evolutionary routes, and clinical parameters, enabling patient risk stratification and individualized outcome estimation.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-domain antibodies were isolated from dromedary camel (VHH) antibody libraries by panning the library with an E6- or E7-derived peptide in complex with HLA-A*02:01. Use of the single-domain antibodies for the detection and treatment of HPV-associated cancers and pre-cancerous lesions is also described.

This specification discloses methods for identifying stable control loci for use in fluorescence in situ hybridization (FISH) assays, and methods for determining whether copy number changes (e.g., amplification) of a target genomic locus (e.g., a gene, e.g., cyclin E1 (CCNE1)) have occurred in a biological sample (e.g., a non-neoplastic sample, a pre-neoplastic lesion, and / or a tumor). In particular, this disclosure provides an expanded repertoire of genomic loci that can serve as stable controls (e.g., stable control loci) for FISH assays aimed at determining copy number changes of a target genomic locus.

Aspects described herein may include a method of diagnosing cervical cancer and pre-cancer conditions, including: utilizing a computer to extract a numerical value corresponding to an order parameter squared (S2) from image data from at least one image of cervical tissue / cells from a patient, wherein the image data includes at least one region having light regions and dark regions, and wherein S2 includes a numerical value quantifying a degree of order present in the image data, and wherein the extracted numerical value comprises a ratio of an area of the light regions to a total area; comparing the extracted numerical value to one or more predefined diagnosis ranges corresponding to stages of cervical cancer and pre-cancer conditions; and diagnosing the stage of the cervical cancer and pre-cancer conditions if the numerical value of the S2 falls within one of the predefined diagnosis ranges.

The invention discloses a library construction method for non-HPV (human papillomavirus) related cervical tumor and precancerous lesion molecular subtypes thereof based on high-throughput sequencing, which comprises the following steps: ultrasonically breaking genome DNA (deoxyribonucleic acid) of a detected sample to obtain a DNA fragment, modifying the tail end, connecting a joint, and performing purification and pre-amplification reaction, namely performing hybridization reaction on a pre-amplification sequence by using a hybridization capture reagent, according to the method, a hybridization capture reagent is adopted, DNA fragments combined through non-specific capture are enriched and removed, then an amplification reaction is carried out, a library is obtained, next-generation sequencing is carried out, original data are subjected to bioinformatics analysis, variation information is obtained, and the hybridization capture reagent comprises specific primers with the sequences shown as SEQ ID NO: 1-175. According to the present invention, the integration of the non-HPV-related cervical tumor and precancerous lesion molecule detection is achieved, the detection can be completed in one experiment, and the sequencing depth is improved by specifically enriching the target region so as to improve the sensitivity of the non-HPV-related cervical tumor and precancerous lesion molecule detection.

The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.

The invention discloses a traditional Chinese medicine composition for treating intestinal tract diseases, which is prepared from the following traditional Chinese medicines in parts by weight: 8-15 parts of selfheal, 20-40 parts of nacre mother of pearl, 5-10 parts of radix bupleuri, 3-8 parts of fried fructus aurantii, 3-8 parts of rhizoma cyperi, 6-12 parts of inula flower and 5-9 parts of pericarpium citri reticulatae. The traditional Chinese medicine composition can be used for pertinently treating liver and gall stagnated heat, stomach qi reversal type bile reflux gastritis or gastroesophageal reflux disease, has the specific treatment effects of relieving inflammation, inhibiting local tissue angiogenesis and preventing precancerous lesions and / or canceration, and has good clinical significance.

The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising a) detecting the presence or absence of an antibody to ANPEP (Aminopeptidase N, anti-ANPEP antibody) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the presence or absence of an antibody to ANPEP determined in step a). The present invention further relates to computer-implemented methods, databases, devices, kits and uses related thereto.

The present application provides the application of Rabdosia serra extract in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the Rabdosia serra extract includes Rabdosia serra aerial part extract, Rabdosia serra underground part extract, Rabdosia serra total part extract and eluate thereof, etc. The present application also provides the application of compounds in Rabdosia serra in the preparation of drugs for treating atrophic gastritis and precancerous lesions of gastric cancer, wherein the compounds in Rabdosia serra are selected from oridonin, rabdosin C, norcantharidin, raxofelone and rabdosiin A. The present application proves that Rabdosia serra extract and the compounds in Rabdosia serra have good activity of reversing precancerous lesions of gastric cancer by constructing a cell model (MC cell model) of atrophic gastritis and precancerous lesions of gastric cancer by stimulating GES-1 cells with MNNG.

The invention relates to the technical field of molecule and cell biology, and discloses a preparation method of a polygene methylation detection kit based on fecal DNA, which comprises the following steps: preparing a specific primer and probe mixture: the mixture comprises specific primers and probes for detecting methylation states of BMP3, NDRG4, TFPI2, SDC2 and SFRP2 genes, and internal reference primers and probes for detecting ACTB genes; according to the invention, five genes of BMP3, NDRG4, TFPI2, SDC2 and SFRP2 are adopted for joint detection. The multi-gene combination strategy can effectively overcome the limitation that a single gene methylation signal is deleted or unstable in part of early cancer or precancerous lesions, and the detection rate (sensitivity) of colorectal cancer, especially early colorectal cancer, is greatly improved through multi-target and multi-channel coverage.

The invention discloses a multi-omics disease prediction model-based construction method, equipment, a medium and a program product, which are applied to the field of intelligent medical detection. The method comprises the following steps: preprocessing multi-omics original data; cross-omics association feature screening is performed through a dynamic feature selection mechanism fusing mutual information entropy, omics weight and KL divergence, and dynamic update features are dynamically generated based on local density and category weight; according to the method, multi-omics information can be effectively fused, the discrimination of feature selection, the training stability and the recognition capability of early gastric cancer and precancerous lesions are improved, and the method has relatively high clinical application value.

The invention provides an artificial-intelligence–based platform for automated analysis of Pap smear slides. The system integrates preprocessing, dual deep learning models (CNN-Transformer and EfficientNet-LSTM), and reporting modules to classify cytological images into diagnostic categories including NILM, ASC-US, LSIL, HSIL, and SCC. The platform includes interpretability outputs, secure data management, and active learning capabilities, enabling scalable, accurate, and transparent cervical-cancer screening across diverse laboratory settings. The platform is suitable for implementation in clinical pathology laboratories, telemedicine networks, and population-level screening programs. It allows rapid, reproducible, and objective evaluation of cytology slides, improving throughput while reducing reliance on manual slide examination. The invention is deployable on local servers, private clouds, or public cloud infrastructures and is adaptable to various cytology specimens. Adoption of this system enhances early detection of precancerous lesions, reduces inter-observer variability, and facilitates integration with laboratory information systems. It also supports continuous learning and adaptation to evolving imaging protocols. The invention provides multiple advantages over existing methods: (1) Dual-model architecture combining CNN-Transformer and EfficientNet- LSTM ensures robust classification across both dense and sparse cellular regions. (2)Preprocessing and adaptive tiling improve feature extraction from variable-quality images. (3)Interpretability modules enhance clinician trust and facilitate regulatory compliance. (4) Active learning allows continuous improvement based on expert feedback. (5) Modular deployment supports both local laboratory and cloud-based operation. (6) Data security features meet international standards for privacy and encryption. (7) High scalability enables screening of large slide volumes without compromising accuracy. The invention provides a clinically relevant, efficient, and technologically advanced solution for automated cervical-cancer screening, applicable in diverse healthcare environments and adaptable to future cytology domains.

Applicant provides herein methods for treating a patient having a pre-cancerous oral leukoplakia (LK) lesion or for delaying the progression of a pre-cancerous oral LK to oral squamous cell carcinoma. It also provides methods to identify patients that more likely to respond to a therapy comprising administration of an effective amount of an anti-PD-1 or anti-PD-L 1 therapy.

The present application relates to the field of traditional Chinese medicine, and particularly to a composition for treating chronic gastritis and application thereof, the composition is prepared from the following raw materials according to weight fraction: 8-12 parts of Fashanxia, 8-12 parts of Huangqin, 3-7 parts of Huanglian, 4-8 parts of Ganjiang, 12-18 parts of Taizishen, 12-18 parts of Baihuasheshecao, 12-16 parts of Banzhilian, 8-12 parts of E'zhu, 12-20 parts of Chaozhigu, 18-22 parts of Chaoquya, 18-22 parts of Chaomaiya, 8-12 parts of Yujin, 1-5 parts of Sanqi, 8-12 parts of Dazao and 3-8 parts of Zhigancao. The present application effectively solves the problems of lack of specific therapy and specific intervention target for reversing mucosal atrophy, intestinal metaplasia and other precancerous lesions in the prior art, provides a new idea for the mechanism research of CAG treatment by traditional Chinese medicine, and has important theoretical value and clinical conversion prospect for promoting the modernization of traditional Chinese medicine.

The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising (a) determining the level CLEC3B (C-type lectin domain family 3 member B) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the level of CLEC3B determined in step a). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.

The invention is suitable for the technical field of machine learning classification, and provides a voice-based vocal cord tumor multi-classification analysis model training method and system, and the method comprises the following steps: voice data collection; processing data; constructing a model; model training and optimization: inputting the initial tensor into a convolution module, and extracting to obtain an initial feature map; the initial feature map is sequentially sent to a multi-stage LHG module to be processed, and an updated feature map is output; and according to the updated feature map, outputting probability distributions corresponding to three categories of vocal cord polyps, vocal cord precancerous lesions and vocal cord malignant tumors. According to the method, the pathological type of the vocal cord tumor can be noninvasively, accurately and automatically analyzed, and the problems that an existing method depends on invasive biopsy, and an existing intelligent algorithm is insufficient in performance in a multi-classification analysis task are solved.

Non-invasive method for the diagnosis or screening of colorectal cancer and / or pre-cancerous stage thereof. The present invention refers to an in vitro method for the diagnosis of colorectal cancer and / or pre-cancerous stage thereof.

The application discloses a use of a ganoderma lucidum spore and grifola frondosa composition in preparation of a preparation for assisting in relieving colorectal cancer. The composition comprises ganoderma lucidum spore oil, squalene, grifola frondosa extract, selenium-rich yeast and the like, and is prepared into soft capsules by using a cold preparation method. A mouse model experiment induced by AOM / DSS proves that the soft capsules can significantly relieve weight loss of mice, reduce a disease activity index, improve colon shortening, inhibit expression of inflammatory factors TNF-alpha and IL-6 in serum and colon tissues, reduce intestinal inflammatory reactions, repair colon crypt structure and intestinal mucosal damage, down-regulate expression of a proliferation marker Ki 67, up-regulate expression of an apoptosis marker Caspase-3, induce tumor cell apoptosis, regulate intestinal flora structure, restore relative abundance of Bacteroidetes and Firmicutes, and reverse abnormal increase of Verrucomicrobia. The application can act on the whole process from intestinal polyps, precancerous lesions to colorectal cancer development, is safe and stable, can be taken for a long time, and has high application value.

The present invention relates to methods of predicting whether a subject having a cancer or a pre-cancer would benefit from treatment with an immune checkpoint inhibitor, as well as methods for treating subjects determined to be likely to benefit from such treatment.

Disclosed are methods of monitoring minimum residual disease using genomic profiling. In some methods, a subject has or has had multiple myeloma or a precursor thereof. The methods include amplifying a sample using primary template-directed whole genome amplification (PTWGA) and enable monitoring of liquid samples, such as blood samples.

This invention discloses a novel application of undecanoic acid in inducing ferroptosis in laryngeal cancer cells and in the preparation of anti-laryngeal cancer drugs. For the first time, it was discovered that the known compound undecanoic acid can specifically target the mitochondria of laryngeal cancer cells, inducing mitochondrial structural damage and dysfunction. This, in turn, activates the ferroptosis pathway through multiple mechanisms, including increasing intracellular ferrous ion accumulation, increasing lipid peroxide levels, downregulating GPX4 / SLC7A11 expression, and upregulating ACSL4 expression, thereby effectively inhibiting the proliferation of laryngeal cancer cells. Based on this mechanism, this invention provides a pharmaceutical composition with undecanoic acid as the active ingredient, and its combined application with platinum-based drugs (such as cisplatin). This combined treatment exhibits a significant synergistic effect, particularly overcoming the platinum resistance of laryngeal cancer cells. This invention provides a novel drug selection and combination therapy strategy for the treatment and prevention of laryngeal cancer and precancerous lesions.

In the present invention, the inventors reveal that noncoding RNA, a known source of noncanonical peptides (also called dark matter) and tumour-specific antigens, can shape the precancer immune contexture and are associated with polyp and cancer risk. Through the multimodal characterisation of a unique dataset of 135 well-annotated cancer and precancer lesions from patients developing polyps at low and high frequency, the inventors identified high expression of noncoding RNAs, as a major differentiator of polyp development rate. Noncoding RNAs were also associated with increased immunogenicity associated with increased mature tertiary lymphoid structures within the microenvironment of pre-cancer lesion, higher quantity and quality of adaptive immune cells, including B- and T-cells. Thus, the inventors propose that early carcinogenesis is shaped by noncoding RNA expression and immune microenvironment. These compelling findings reveal potential targets for immune modulation approaches in individuals at high risk of developing colorectal cancer. More particularly, the inventors identified dark antigens (i.e. peptides) that can be used in vaccines for the treatment of cancer, in particular, the prophylactic treatment of cancer.

The invention relates to the technical field of Chinese herbal medicines and preparation thereof, in particular to a Chinese herbal medicine composition for treating gastric precancerous lesions and a preparation method thereof. According to the Chinese herbal medicine composition for treating precancerous lesions of gastric cancer, the immature bitter orange, the coptis chinensis and the pinellia ternate are used for promoting the circulation of qi, eliminating mass, relieving qi, removing fullness, reducing stomach heat, eliminating mass and dissipating binds, the rhizoma atractylodis macrocephalae, the malt and the mangnolia officinalis are used for invigorating the spleen, replenishing qi, promoting the circulation of qi and dissipating blood stasis, and the medlar and the Chinese actinidia root are used for at least strengthening the effects of the components; pseudo-ginseng and codonopsis pilosula are utilized to at least play a role in blending the components, damage to the stomach after the effects of the components such as immature bitter orange and coptis chinensis are enhanced is avoided, and meanwhile effective exertion of the medicine effect is guaranteed. Meanwhile, by controlling the mass parts of all the components, the efficacy of the Chinese herbal medicine composition for treating the precancerous lesions of the gastric cancer can be effectively improved. Through mutual cooperation of the components, on the premise that the conditioning effect is guaranteed, the conditioning period can be shortened to 50-100 days, and the overall effect is ideal.

The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising (a) determining the level of SRY-box transcription factor 9 (SOX9) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the level of SOX9 determined in step a). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.

The present invention relates to a method for assessing colorectal cancer or a precancerous condition thereof, said method comprising (a) determining the level CLEC3B (C-type lectin domain family 3 member B) in a blood, serum or plasma sample from the subject, and assessing colorectal cancer or the precancerous condition thereof based on the level of CLEC3B determined in step a). The present invention further relates to computer-implemented methods, databases, devices, and uses related thereto.

The present invention provides pharmaceutical compositions and methods of use of bisbenzylisoquinoline, e.g., 6,6',7,12-tetramethoxy-2,2'-dimethyl-berbaman, and analogs, derivatives, isomers, and modified forms of the compound, e.g., in crystalline, salt, or salt form, in combination with pharmaceutically acceptable acids or other agents, for the treatment of acute, chronic, and preleukemic conditions, as well as lymphoma and solid tumors. These include, but are not limited to, preneoplastic and neoplastic diseases and solid tumors, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), atypical chronic myeloid leukemia (aCML), and acute myeloid leukemia (AML), polycythemia vera (PV), chronic lymphoblastic leukemia (CLL), myeloproliferative syndrome (MPS), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), myelofibrosis (MF), and polycythemia vera (PV).

The invention relates to the technical field of cervical cancer detection, and particularly discloses practical application of HPVE6 / E7mRNA detection in cervical cancer precancerous lesion screening. Comprising the following steps: S1, collecting a cervical cell specimen; s2, carrying out hybridization on the target HPVE6 / E7 mRNA in the specimen and a specific detection probe; s3, performing cascade signal amplification on the hybridization product obtained in S2, and detecting the signal to obtain a semi-quantitative detection result; s4, extracting DNA (deoxyribonucleic acid) from the specimen collected in the step S1, and then carrying out fluorescent quantitative detection so as to quantitatively detect the DNA of the HPV virus; and S5, carrying out statistical analysis on detection results of S3 and S4 by adopting statistical software. The HPVE6 / E7mRNA detection can be used for early screening of cervical cancer, precancerous lesion risk assessment and carcinogenic activity judgment of high-risk HPV infection, and has the advantages that the detection process is synergistic and efficient, and the risk assessment is comprehensive and accurate.